12.07.2015 Views

2007 Winter Meeting - London - The Pathological Society of Great ...

2007 Winter Meeting - London - The Pathological Society of Great ...

2007 Winter Meeting - London - The Pathological Society of Great ...

SHOW MORE
SHOW LESS
  • No tags were found...

You also want an ePaper? Increase the reach of your titles

YUMPU automatically turns print PDFs into web optimized ePapers that Google loves.

O17Receptor Status In DCIS is Variably and InconsistentlyReported: A Study <strong>of</strong> 1684 Cases from <strong>The</strong> Sloane Project{P} JStJ Thomas 1 , AHanby 2 , SE Pinder 3 , JC Macartney 4 ,IO Ellis 5 , K Clements 6 ,HBishop 71 Pathology Dept, Western General Hospital, Edinburgh, 2 Pathology Dept,St James's University Hospital, Leeds, 3 Histopathology Dept,Addenbrookes Hospital, Cambridge, 4 Pathology Dept, UniversityHospital, Coventry, 5 Pathology Dept, City Hospital, Nottingham, 6 WestMidlands Cancer Intelligence Unit, University <strong>of</strong> Birmingham, 7 BreastUnit, Royal Bolton Hospital, Bolton, United Kingdom<strong>The</strong> Sloane Project is an anonymised UK-wide audit <strong>of</strong> screen-detected atypicalhyperplasia and in situ carcinoma <strong>of</strong> the breast. Full pathology data areavailable on 1684 <strong>of</strong> 2615 cases entered. <strong>The</strong>se include oestrogen (ER),progesterone (PGR) and Her2 receptor status and the scoring/cut-<strong>of</strong>f criteria forpositivity used.Results: For hormone receptors, a majority <strong>of</strong> respondents used the Allredscoring system, or a percentage <strong>of</strong> positive cells and a small number the“histoscore”. ER status & grade are given below:Grade High (%) Intermediate (%) Low (%) Unknown Totals (%)994 (59) 491 (29) 180 (11) 19 1684ER pos 325 (69) 198 (94) 79 (99) 602 (79)O18RISK FACTORS FOR LOCAL RECURRENCE INYOUNGER WOMEN WITH BREAST CANCER{P} SE Laird 1 , RA Walker 1 , A Stotter 21 University <strong>of</strong> Leicester, Leicester, United Kingdom, 2 University Hospitals<strong>of</strong> Leicester, Leicester, United KingdomYounger women have higher rates <strong>of</strong> local recurrence (LR) following breastconserving therapy (BCT). This study examined whether this relates topathological features and/or smaller surgical excisions.Clinical and pathological characteristics were assessed for 483 women withearly stage breast cancer who had BCT between 1997 and 2001, and wererelated to margin size, age (≤40 >40 years) and local recurrence. <strong>The</strong>re were 48women ≤40 years <strong>of</strong> age. On univariate analysis grade 3, lymph node status andage ≤40 years related to radial margin <strong>of</strong> excision < 3mm, and grade 3, presence<strong>of</strong> high grade DCIS and age ≤40 years with small all margins. Logisticregression analysis showed that age ≤40 years, grade 3 and Infiltrating LobularCarcinoma were associated with radial margin < 3mm. Grade 3 and presence <strong>of</strong>vascular invasion (VI) were associated with age ≤40 years on univariateanalysis but on multivariate analysis only breast volume and excision volumewere associated with younger age. Actuarial survival curves showed presence<strong>of</strong> VI, high grade DCIS and grade 3 to decrease LR free survival.More aggressive pathological features are associated with LR and couldincrease this in women ≤40 years <strong>of</strong> age, but smaller breasts and excisionvolumes are also important factors.ER neg 148 (31) 12 (6) 1 (1) 161 (21)Unknown 521 281 100ER positivity in low and intermediate grade DCIS was significantly morefrequent than in high grade DCIS (p65 years though research efforts arespent mainly on younger patients. Knowledge on elderly breast cancer isurgently needed.Patients >70 years who had early operable primary breast cancer(0 – 50 26 1.73 141 17.1 >50 – 100 63 4Total 826 100 >100 – 200 493 31.7>200 – 300 691 44.4Total 1,557 100Among 44 DCIS which were graded, most (52.3%) were high grade.We believe that this is the largest dataset <strong>of</strong> pathological features <strong>of</strong>primary breast cancer in the elderly from one single centre. Further work isunderway to correlate them with the long-term clinical outcome.O20Her2 expression: Correlation <strong>of</strong> Chromogenic In-situHybridization with Immunohistochemistry and FluorescentIn-situ Hybridization{P} M Sohail 1 ,NBanu 1 , CJ Calder 2 , S Mungwana 2 ,SFlorio 2 ,FLewis 3 ,MMoorghen 2 , M Pignatelli 1 ,AHanby 31 University <strong>of</strong> Bristol, Bristol, United Kingdom, 2 Bristol Royal Infirmary,Bristol, United Kingdom, 3 University <strong>of</strong> Leeds, Leeds, United KingdomHer2 gene is located on chromosome 17 and encodes a growth factor receptor.Her2 amplification is a prognostic marker and its assessment is also required toplan the treatment <strong>of</strong> breast cancer with Herceptin. Immunohistochemistry(IHC) is used in the first instance to determine Her2 status <strong>of</strong> the breast cancer.Equivocal (2+) cases are further tested for gene amplification by fluorescent insituhybridization (FISH). In this study we compared the recently describedchromogenic in-situ hybridization (CISH) method for Her2 assessment withFISH and IHC.Methods: 94 cases <strong>of</strong> breast cancer were selected from the archives <strong>of</strong>Department <strong>of</strong> Histopathology <strong>of</strong> the Bristol Royal Infirmary. IHC was carriedout by indirect immunoperoxidase using anti-HER2 monoclonal antibody(Dako A0485) FISH and CISH were performed using specific probes from Q-BIOgene (PONCHER2) and Zymed Lab (84-0146) respectively.Results: IHC score was 0 in 28, 1+ in 29, 2+ in 20, and 3+ in 17 cases. Her2gene was amplified in all 3+ cases and not amplified in 0 and 1+ cases on FISHand CISH tests. <strong>The</strong>re was no discrepancy between FISH and CISH results in2+ cases.Conclusion: CISH is a reliable, alternative and quick method for the Her2assessment in breast cancer.54 <strong>Winter</strong> <strong>Meeting</strong> (191 st ) 3–5 January <strong>2007</strong> Scientific Programme

Hooray! Your file is uploaded and ready to be published.

Saved successfully!

Ooh no, something went wrong!